DiaSorin (DSRLF) Stock Forecast & Price Target

$99.86

-9.14 (-8.39%)

(As of 06/27/2024)

DiaSorin - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold

Based on 1 Analyst Ratings

Sell
0

Hold
1

Buy
0

Based on 1 Wall Street analysts who have issued ratings for DiaSorin in the last 12 months, the stock has a consensus rating of "Hold." Out of the 1 analysts, 1 has given a hold rating for DSRLF.

Consensus Price Target

N/A

Get the Latest News and Ratings for DSRLF and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for DiaSorin and its competitors.

DSRLF Analyst Ratings Over Time

Type	Current Forecast 10/8/23 to 10/7/24	1 Month Ago 9/8/23 to 9/7/24	3 Months Ago 7/10/23 to 7/9/24	1 Year Ago 10/8/22 to 10/8/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	0 Buy rating(s)	0 Buy rating(s)	0 Buy rating(s)	1 Buy rating(s)
Hold	1 Hold rating(s)	1 Hold rating(s)	1 Hold rating(s)	2 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	3 Sell rating(s)
Consensus Price Target	N/A	N/A	N/A	N/A
Forecasted Upside	N/A	N/A	N/A	N/A
Consensus Rating	Hold	Hold	Hold	Reduce

Notice: Major payout due November 19th - are you on the list? (Ad)

On Tuesday, November 19, 2024 smart investors will collect their share of a $1.2 billion windfall... It's part of a unique strategy which has nothing to do with risky investments like options, cryptos or forex. And while it might sound crazy...

Click here for the ticker >>>

DSRLF Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

DSRLF Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

DiaSorin Stock vs. The Competition

Type	DiaSorin	Medical Companies	S&P 500
Consensus Rating Score	2.00	2.78	2.50
Consensus Rating	Hold	Moderate Buy	Moderate Buy
Predicted Upside	N/A	12,557.31% Upside	7.04% Upside
News Sentiment Rating	Neutral News See Recent DSRLF News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target
5/9/2024	Barclays 3 of 5 stars		Initiated Coverage	Equal Weight
4/3/2023	Kepler Capital Markets 4 of 5 stars		Downgrade	Hold ➝ Reduce
3/20/2023	Morgan Stanley 3 of 5 stars		Downgrade	Equal Weight ➝ Underweight
3/9/2023	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Neutral ➝ Underperform
3/7/2023	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Hold ➝ Buy
11/29/2022	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Hold
11/8/2022	Berenberg Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		€170.00 ➝ €153.00
10/31/2022	Exane BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating	Hugo Solvet Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underperform ➝ Neutral	€135.00

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 06:31 AM ET.

DSRLF Forecast - Frequently Asked Questions

: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for DiaSorin in the last twelve months. There is currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" DSRLF shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DSRLF, but not buy additional shares or sell existing shares.
: According to analysts, DiaSorin's stock has a predicted downside of -100.00% based on their 12-month stock forecasts.
: Analysts like DiaSorin less than other "medical" companies. The consensus rating for DiaSorin is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how DSRLF compares to other companies.